peripheral interest, re. RSV......
Thursday June 29, 9:02 am Eastern Time
Company Press Release
SOURCE: Abbott Laboratories
Abbott Laboratories and Battelle Pulmonary
Therapeutics Announce License Agreement
ABBOTT PARK, Ill., June 29 /PRNewswire/ -- Abbott Laboratories, Ross Products Division and Battelle Pulmonary
Therapeutics, Inc. (BPT), announced today an agreement under which BPT will license to Abbott new products and drug
delivery technology to develop therapies for a variety of respiratory diseases.
``Battelle and Abbott have had a long, successful history in the development of proprietary devices for the delivery of nutritional
products,'' said Joy Amundson, senior vice president, Ross Products Division. ``We look forward to expanding this relationship
into the area of pharmaceutical products for respiratory diseases.''
``We are very encouraged by this business relationship and the laboratory work we have done so far on new pulmonary
therapies,'' said Dennis Cearlock, president and chief executive officer, Battelle Pulmonary Therapeutics, a subsidiary of
Battelle Memorial Institute. ``Abbott has formulation and manufacturing expertise in proprietary respiratory disease compounds
and BPT has expertise in drug delivery device technology. The collaboration between the two companies' research groups will
provide a critical mass to develop new therapies together and move forward with clinical development.''
Terms of the agreement were not disclosed.
Battelle Pulmonary Therapeutics is a for-profit subsidiary of Battelle Memorial Institute. It focuses on developing pulmonary
drug products and medical devices that can treat respiratory and systemic diseases. Both Battelle Pulmonary Therapeutics and
Battelle Memorial Institute are located in Columbus, Ohio.
The Ross Products Division of Abbott Laboratories is a longtime leader in the United States nutritional marketplace,
well-known for its leading Similac© infant formula and Ensure© adult nutritional products. The Ross Products Division is
building on this foundation to develop a portfolio of novel pediatric pharmaceuticals and specialty pharmaceuticals.
Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and
marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company employs 57,000 people and markets
its products in more than 130 countries. In 1999, the Company's sales and net earnings were $13.2 billion and $2.4 billion,
respectively.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com .
SOURCE: Abbott Laboratories |
